Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

被引：0
|
作者：
Mathew Vithayathil
Antonio D’Alessio
Claudia Angela Maria Fulgenzi
Naoshi Nishida
Martin Schönlein
Johann von Felden
Kornelius Schulze
Henning Wege
Anwaar Saeed
Brooke Wietharn
Hannah Hildebrand
Linda Wu
Celina Ang
Thomas U. Marron
Arndt Weinmann
Peter R. Galle
Dominik Bettinger
Bertram Bengsch
Arndt Vogel
Lorenz Balcar
Bernhard Scheiner
Pei-Chang Lee
Yi-Hsiang Huang
Suneetha Amara
Mahvish Muzaffar
Abdul Rafeh Naqash
Antonella Cammarota
Valentina Zanuso
Tiziana Pressiani
Matthias Pinter
Alessio Cortellini
Masatoshi Kudo
Lorenza Rimassa
David J. Pinato
Rohini Sharma
机构：
[1] Imperial College London,Department of Surgery & Cancer
[2] Hammersmith Campus,Department of Biomedical Sciences
[3] Humanitas University,Division of Medical Oncology
[4] Policlinico Universitario Campus Bio-Medico,Department of Gastroenterology and Hepatology, Faculty of Medicine
[5] Kindai University,Department of Oncology, Hematology and Bone Marrow Transplantation With Section of Pneumology
[6] University Medical Center Hamburg-Eppendorf,Department of Gastroenterology and Hepatology
[7] University Medical Center Hamburg-Eppendorf,Division of Medical Oncology, Department of Medicine
[8] Kansas University Cancer Center,Division of Hematology/Oncology, Department of Medicine
[9] Tisch Cancer Institute,I. Medical Department
[10] Mount Sinai Hospital,Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases), Faculty of Medicine
[11] University Medical Center Mainz,Division of Gastroenterology & Hepatology, Department of Internal Medicine III
[12] Freiburg University Medical Center,Division of Gastroenterology and Hepatology, Department of Medicine
[13] University of Freiburg,Institute of Clinical Medicine, School of Medicine
[14] University of Freiburg,Division of Hematology/Oncology
[15] Signalling Research Centers BIOSS and CIBSS,Medical Oncology and Hematology Unit
[16] German Cancer Consortium (DKTK),Division of Oncology, Department of Translational Medicine
[17] Hannover Medical School,undefined
[18] Medical University of Vienna,undefined
[19] Taipei Veterans General Hospital,undefined
[20] National Yang Ming Chiao Tung University,undefined
[21] East Carolina University,undefined
[22] Medical Oncology/TSET Phase 1 Program,undefined
[23] Stephenson Cancer Center,undefined
[24] University of Oklahoma,undefined
[25] Humanitas Cancer Center,undefined
[26] IRCCS Humanitas Research Hospital,undefined
[27] University of Piemonte Orientale,undefined
来源：
Hepatology International | 2023年 / 17卷
关键词：
Immunotherapy; Anti-programmed death-ligand; Anti-vascular endothelial growth factor; Checkpoint inhibitor; Obesity; Cirrhosis; Overall survival; Progression-free survival; Overweight; Non-alcoholic fatty liver disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：904 / 914
页数：10
相关论文
共 50 条
  • [31] Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study
    Takeshi Hatanaka
    Satoru Kakizaki
    Atsushi Hiraoka
    Toshifumi Tada
    Masashi Hirooka
    Kazuya Kariyama
    Joji Tani
    Masanori Atsukawa
    Koichi Takaguchi
    Ei Itobayashi
    Shinya Fukunishi
    Kunihiko Tsuji
    Toru Ishikawa
    Kazuto Tajiri
    Hironori Ochi
    Satoshi Yasuda
    Hidenori Toyoda
    Chikara Ogawa
    Takashi Nishimura
    Noritomo Shimada
    Kazuhito Kawata
    Hisashi Kosaka
    Takaaki Tanaka
    Hideko Ohama
    Kazuhiro Nouso
    Asahiro Morishita
    Akemi Tsutsui
    Takuya Nagano
    Norio Itokawa
    Tomomi Okubo
    Taeang Arai
    Michitaka Imai
    Atsushi Naganuma
    Yohei Koizumi
    Shinichiro Nakamura
    Kouji Joko
    Masaki Kaibori
    Hiroko Iijima
    Yoichi Hiasa
    Takashi Kumada
    Hepatology International, 2022, 16 : 1150 - 1160
  • [32] Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma
    Li, Binghua
    Wen, Jingyuan
    Xu, Zhu
    Yan, Peng
    Han, Bing
    Yu, Decai
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [33] Lean body mass index is a marker of advanced tumor features in patients with hepatocellular carcinoma
    deLemos, Andrew Scott
    Zhao, Jing
    Patel, Milin
    Kooken, Banks
    Mathur, Karan
    Nguyen, Hieu Minh
    Mazhar, Areej
    McCarter, Maggie
    Burney, Heather
    Kettler, Carla
    Chalasani, Naga
    Gawrieh, Samer
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03) : 393 - 404
  • [34] Negative impact of low body mass index on surgical outcomes after hepatectomy for hepatocellular carcinoma
    Okamura, Yukiyasu
    Maeda, Atsuyuki
    Matsunaga, Kazuya
    Kanemoto, Hideyuki
    Uesaka, Katsuhiko
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2012, 19 (04) : 449 - 457
  • [35] Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
    Fukushima, Taito
    Morimoto, Manabu
    Kobayashi, Satoshi
    Ueno, Makoto
    Uojima, Haruki
    Hidaka, Hisashi
    Kusano, Chika
    Chuma, Makoto
    Numata, Kazushi
    Tsuruya, Kota
    Arase, Yoshitaka
    Kagawa, Tatehiro
    Hattori, Nobuhiro
    Ikeda, Hiroki
    Watanabe, Tsunamasa
    Tanaka, Katsuaki
    Maeda, Shin
    ONCOLOGIST, 2023, 28 (07) : E526 - E533
  • [36] Remaining Issues Related to Serum Cytokines in Patients with Unresectable Hepatocellular Carcinoma Treated by Atezolizumab plus Bevacizumab Combination Treatment
    Nagai, Hidenari
    Mukozu, Takanori
    Matsui, Teppei
    Mohri, Kunihide
    Nagumo, Hideki
    Yoshimine, Naoyuki
    Kobayashi, Kojiro
    Ogino, Yu
    Daido, Yasuko
    Wakui, Noritaka
    Momiyama, Koichi
    Matsuda, Takahisa
    Igarashi, Yoshinori
    Higai, Koji
    ONCOLOGY, 2024, 102 (10) : 828 - 840
  • [37] Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
    Fei Cao
    Changsheng Shi
    Guofu Zhang
    Jun Luo
    Jiaping Zheng
    Weiyuan Hao
    BMC Cancer, 23 (1)
  • [38] Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
    Cao, Fei
    Shi, Changsheng
    Zhang, Guofu
    Luo, Jun
    Zheng, Jiaping
    Hao, Weiyuan
    BMC CANCER, 2023, 23 (01)
  • [39] The impact of body mass index on prognosis in patients with colon carcinoma
    Julian Fuchs
    Vera S Schellerer
    Maximilian Brunner
    Carol I Geppert
    Robert Grützmann
    Klaus Weber
    Susanne Merkel
    International Journal of Colorectal Disease, 2022, 37 : 1107 - 1117
  • [40] Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort
    Jost-Brinkmann, Fabian
    Demir, Muenevver
    Wree, Alexander
    Luedde, Tom
    Loosen, Sven H.
    Mueller, Tobias
    Tacke, Frank
    Roderburg, Christoph
    Mohr, Raphael
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (11) : 1313 - 1325
12345